216 related articles for article (PubMed ID: 24080992)
1. RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Kachnic LA; Pugh SL; Tai P; Smith M; Gore E; Shah AB; Martin AG; Kim HE; Nabid A; Lawton CA
Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):382-6. PubMed ID: 24080992
[TBL] [Abstract][Full Text] [Related]
2. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
3. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
4. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
5. Impact of androgen suppression and zoledronic acid on bone mineral density and fractures in the Trans-Tasman Radiation Oncology Group (TROG) 03.04 Randomised Androgen Deprivation and Radiotherapy (RADAR) randomized controlled trial for locally advanced prostate cancer.
Denham JW; Nowitz M; Joseph D; Duchesne G; Spry NA; Lamb DS; Matthews J; Turner S; Atkinson C; Tai KH; Gogna NK; Kenny L; Diamond T; Smart R; Rowan D; Moscato P; Vimieiro R; Woodfield R; Lynch K; Delahunt B; Murray J; D'Este C; McElduff P; Steigler A; Kautto A; Ball J
BJU Int; 2014 Sep; 114(3):344-53. PubMed ID: 24512527
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
[TBL] [Abstract][Full Text] [Related]
7. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
[TBL] [Abstract][Full Text] [Related]
8. Long term zoledronic acid during androgen blockade for prostate cancer.
Casey R; Gesztesi Z; Rochford J
Can J Urol; 2010 Jun; 17(3):5170-7. PubMed ID: 20566009
[TBL] [Abstract][Full Text] [Related]
9. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer.
Yee CH; Ng CF; Wong AY; Chan CK; Hou SM; Yip SK
Asia Pac J Clin Oncol; 2011 Jun; 7(2):168-73. PubMed ID: 21585697
[TBL] [Abstract][Full Text] [Related]
11. Suppression of bone density loss and bone turnover in patients with hormone-sensitive prostate cancer and receiving zoledronic acid.
Ryan CW; Huo D; Bylow K; Demers LM; Stadler WM; Henderson TO; Vogelzang NJ
BJU Int; 2007 Jul; 100(1):70-5. PubMed ID: 17552955
[TBL] [Abstract][Full Text] [Related]
12. Annual zoledronic acid: is less more?
Higano CS
J Clin Oncol; 2007 Mar; 25(9):1026. PubMed ID: 17369565
[No Abstract] [Full Text] [Related]
13. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
16. Atypical femoral shaft fracture in a patient with non-metastatic prostate cancer on zoledronic acid therapy: effect of therapy or coincidence?
Reddy SV; Gupta SK
Singapore Med J; 2012 Mar; 53(3):e52-4. PubMed ID: 22434305
[TBL] [Abstract][Full Text] [Related]
17. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
[TBL] [Abstract][Full Text] [Related]
18. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
[TBL] [Abstract][Full Text] [Related]
19. Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Cai T; Bartoletti R
J Clin Oncol; 2007 Aug; 25(22):3385; author reply 3385-6. PubMed ID: 17664492
[No Abstract] [Full Text] [Related]
20. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]